Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
Explore the FDA-cleared Modius Stress, offering groundbreaking ease in managing generalized anxiety with daily 30-minute sessions, showing significant reductions in GAD-7 scores in international clinical trials.
Psychiatry May 14th 2024
OBR Oncology
Enhertu, now FDA approved for HER2-positive solid tumors, shows a notable objective response rate across pivotal trials, providing a significant new option for patients with advanced disease stages.
Oncology, Medical May 13th 2024
Psych Congress Network
Rejoyn represents a significant advancement in the treatment of major depressive disorder, requiring prescription use and integrating brain-training exercises developed by leading mental health experts.
Psychiatry May 7th 2024
MedTech Dive
The recent FDA approval of Lumicell’s breast cancer imaging system introduces a novel intraoperative tool that significantly enhances the precision of tumor resections, potentially reducing the need for subsequent corrective surgeries.
Oncology, Surgical April 22nd 2024
Zevtera® (ceftobiprole medocaril) provides a significant advancement in treating serious bacterial infections, demonstrating high efficacy against both MRSA and MSSA in recent phase 3 clinical trials.
Infectious Diseases April 18th 2024
Explore the potential of Rejoyn™, a digital therapeutic now cleared by the FDA, which has shown to significantly reduce depressive symptoms in adults as an adjunct to traditional outpatient care, without any reported adverse events.
Psychiatry April 9th 2024